Employees: 11 (2023.0)Legal category: 5785Size: PMECreation date: 2009-11-12 (16 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: ANTIBES (06600), Alpes-Maritimes
PHARMANTIBES : revenue, balance sheet and financial ratios
PHARMANTIBES is a French company
founded 16 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in ANTIBES (06600),
this company of category PME
shows in 2021 a revenue of 3.3 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - PHARMANTIBES (SIREN 518100045)
Indicator
2023
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue
N/C
3 264 068 €
2 880 059 €
2 561 529 €
2 306 121 €
2 122 229 €
2 090 848 €
2 053 103 €
2 023 905 €
1 970 303 €
Net income
75 818 €
260 814 €
127 783 €
116 488 €
79 466 €
119 105 €
104 924 €
100 660 €
67 512 €
75 336 €
EBITDA
N/C
360 993 €
203 125 €
185 060 €
139 096 €
197 943 €
162 715 €
195 272 €
156 508 €
163 690 €
Net margin
N/C
8.0%
4.4%
4.5%
3.4%
5.6%
5.0%
4.9%
3.3%
3.8%
Revenue and income statement
In 2023, PHARMANTIBES generates positive net income of 76 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2013-2023: 75 k€ -> 76 k€.
Net income (2023)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
75 818 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 0%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 76%. This high autonomy means the company finances most of its assets through equity, a sign of strength.
Debt ratio (2023)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
0.055%
Financial autonomy (2023)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
76.33%
Asset age ratio (2023)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2013
2014
2015
2016
2017
2018
2019
2020
2021
2023
Debt ratio
324.871
242.378
161.611
114.528
92.621
57.683
39.367
24.126
6.419
0.055
Financial autonomy
19.69
23.866
32.419
38.152
44.721
51.706
57.313
64.841
72.339
76.33
Repayment capacity
7.862
7.438
5.003
5.206
3.505
3.841
2.336
1.302
0.281
None
Cash flow / Revenue
5.993%
5.641%
7.147%
5.763%
7.145%
4.804%
5.489%
5.391%
8.272%
None%
Sector positioning
Debt ratio
0.062023
2020
2021
2023
Q1: 20.09
Med: 66.92
Q3: 169.22
Excellent
In 2023, the debt ratio of PHARMANTIBES (0.06) ranks in the bottom 25% of the sector, which is positive. This ratio measures the weight of debt relative to equity. A low ratio indicates a solid financial structure with little dependence on creditors.
Financial autonomy
76.33%2023
2020
2021
2023
Q1: 28.71%
Med: 48.51%
Q3: 68.18%
Excellent
In 2023, the financial autonomy of PHARMANTIBES (76.3%) ranks in the top 25% of the sector. This ratio represents the share of equity in total financing. High autonomy reflects financial independence and ability to absorb shocks.
Repayment capacity
0.28 years2021
2020
2021
Q1: 1.06 years
Med: 3.56 years
Q3: 7.31 years
Excellent
In 2021, the repayment capacity of PHARMANTIBES (0.28) ranks in the bottom 25% of the sector, which is positive. This ratio indicates the number of years needed to repay debt with cash flow. A short capacity reflects controlled debt and good cash generation.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 195.25. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2023)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
195.255
Liquidity indicators evolution PHARMANTIBES
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2013
2014
2015
2016
2017
2018
2019
2020
2021
2023
Liquidity ratio
144.98
137.323
163.955
155.726
166.731
166.687
166.52
162.272
184.3
195.255
Interest coverage
15.41
14.856
10.202
7.562
4.898
5.212
3.19
2.383
0.578
None
Sector positioning
Liquidity ratio
195.252023
2020
2021
2023
Q1: 135.26
Med: 189.75
Q3: 270.27
Good+12 pts over 3 years
In 2023, the liquidity ratio of PHARMANTIBES (195.25) ranks above the median of the sector. This ratio measures the ability to cover short-term debt with current assets. This comfortable position offers an appreciable safety margin.
Interest coverage
0.58x2021
2020
2021
Q1: 0.27x
Med: 2.43x
Q3: 5.92x
Average-10 pts over 2 years
In 2021, the interest coverage of PHARMANTIBES (0.6x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2023)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2023)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2023)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2023)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution PHARMANTIBES
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2013
2014
2015
2016
2017
2018
2019
2020
2021
2023
Operating WCR
266 700 €
285 371 €
279 078 €
333 846 €
320 987 €
342 113 €
326 134 €
369 051 €
334 926 €
0 €
Inventory turnover (days)
55
53
53
57
57
56
52
48
44
0
Customer payment term (days)
5
2
3
7
4
1
1
3
3
0
Supplier payment term (days)
37
40
34
42
35
40
40
36
39
0
Positioning of PHARMANTIBES in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 220 transactions of similar company sales
in 2023,
the value of PHARMANTIBES is estimated at
894 612 €
(range 544 056€ - 1 257 624€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2023
220 transactions
544k€894k€1257k€
894 612 €Range: 544 056€ - 1 257 624€
NAF 5 année 2023
Valuation method used
Net Income Multiple
75 818 €
×
11.8x
=894 613 €
Range: 544 057€ - 1 257 625€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 220 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare PHARMANTIBES with other companies in the same sector:
Yes, PHARMANTIBES generated a net profit of 76 k€ in 2023.
Where is the headquarters of PHARMANTIBES ?
The headquarters of PHARMANTIBES is located in ANTIBES (06600), in the department Alpes-Maritimes.
Where to find the tax return of PHARMANTIBES ?
The tax return of PHARMANTIBES is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does PHARMANTIBES operate?
PHARMANTIBES operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart